Human B cell-derived lymphoblastoid cell lines constitutively produce Fas ligand and secrete MHCII+FasL+ killer exosomes

Frontiers in Immunology

Volumn 5, Issue APR, 2014, Pages

  Klinker, Matthew W ^a,b   Lizzio, Vincent ^b   Reed, Tamra J ^b   Fox, David A ^a,b   Lundy, Steven K ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Epstein Barr virus; Killer B cells; Lethal exosomes; Microvesicles; Regulatory B cells; T cell apoptosis; Transplant tolerance

Indexed keywords

FAS LIGAND;

APOPTOSIS; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CELL ASSAY; CELL CULTURE; CELL FUNCTION; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; EXOSOME; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOBLOTTING; LYSOSOME; MAJOR HISTOCOMPATIBILITY COMPLEX; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

EID: 84900846899     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00144     Document Type: Article

References (57)

1. +) T-cell subsets in transplantation. Immunol Rev (2013) 252(1):183-91. doi:10.1111/imr.12038.
2. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med (1996) 183(3):1161-72. doi:10.1084/jem.183.3.1161.
3. Kim SH, Lechman ER, Bianco N, Menon R, Keravala A, Nash J, et al. Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J Immunol (2005) 174(10):6440-8.
4. Kim SH, Bianco N, Menon R, Lechman ER, Shufesky WJ, Morelli AE, et al. Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive. Mol Ther (2006) 13(2):289-300. doi:10.1016/j.ymthe.2005.09.015.
5. Kim SH, Bianco NR, Shufesky WJ, Morelli AE, Robbins PD. MHC class II+ exosomes in plasma suppress inflammation in an antigen-specific and Fas ligand/Fas-dependent manner. J Immunol (2007) 179(4):2235-41.
6. Pêche H, Renaudin K, Beriou G, Merieau E, Amigorena S, Cuturi MC. Induction of tolerance by exosomes and short-term immunosuppression in a fully MHC-mismatched rat cardiac allograft model. Am J Transplant (2006) 6(7):1541-50. doi:10.1111/j.1600-6143.2006.01344.x.
7. Ohkura N, Kitagawa Y, Sakaguchi S. Development and maintenance of regulatory T cells. Immunity (2013) 38(3):414-23. doi:10.1016/j.immuni.2013.03.002.
8. Lundy SK. Killer B lymphocytes: the evidence and the potential. Inflamm Res (2009) 58(7):345-57. doi:10.1007/s00011-009-0014-x.
9. Hahne M, Renno T, Schroeter M, Irmler M, French L, Bornard T, et al. Activated B cells express functional Fas ligand. Eur J Immunol (1996) 26(3):721-4. doi:10.1002/eji.1830260332.
10. Villunger A, Egle A, Marschitz I, Kos M, Böck G, Ludwig H, et al. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood (1997) 90(1):12-20.
11. + T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood (1998) 91(11):4273-81.
12. Kojima Y, Tsurumi H, Goto N, Shimizu M, Kasahara S, Yamada T, et al. Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome. Eur J Haematol (2006) 76(6):465-72. doi:10.1111/j.1600-0609.2006.00631.x.
13. Lundy SK, Lerman SP, Boros DL. Soluble egg antigen-stimulated T helper lymphocyte apoptosis and evidence for cell death mediated by FasL(+) T and B cells during murine Schistosoma mansoni infection. Infect Immun (2001) 69(1):271-80. doi:10.1128/IAI.69.1.271-280.2001.
14. Tian J, Zekzer D, Hanssen L, Lu Y, Olcott A, Kaufman DL. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J Immunol (2001) 167(2):1081-9.
15. Lundy SK, Fox DA. Reduced Fas ligand-expressing splenic CD5+ B lymphocytes in severe collagen-induced arthritis. Arthritis Res Ther (2009) 11(4):R128. doi:10.1186/ar2795.
16. Mabrouk I, Buart S, Hasmim M, Michiels C, Connault E, Opolon P, et al. Prevention of autoimmunity and control of recall response to exogenous antigen by Fas death receptor ligand expression on T cells. Immunity (2008) 29(6):922-33. doi:10.1016/j.immuni.2008.10.007.
17. Montandon R, Korniotis S, Layseca-Espinosa E, Gras C, Mégret J, Ezine S, et al. Innate pro-B-cell progenitors protect against type 1 diabetes by regulating autoimmune effector T cells. Proc Natl Acad Sci U S A (2013) 110(24):E2199-208. doi:10.1073/pnas.1222446110.
18. Bonardelle D, Benihoud K, Kiger N, Bobé P. B lymphocytes mediate Fas-dependent cytotoxicity in MRL/lpr mice. J Leukoc Biol (2005) 78(5):1052-9. doi:10.1189/jlb.0904536.
19. Minagawa R, Okano S, Tomita Y, Kishihara K, Yamada H, Nomoto K, et al. The critical role of Fas-Fas ligand interaction in donor-specific transfusion-induced tolerance to H-Y antigen. Transplantation (2004) 78(6):799-806. doi:10.1097/01.TP.0000129799.96439.6F.
20. Tosato G, Cohen JI. Generation of Epstein-Barr Virus (EBV)-immortalized B cell lines. Curr Protoc Immunol (2007) Chapter 7:Unit722. doi:10.1002/0471142735.im0722s76.
21. Haas CS, Creighton CJ, Pi X, Maine I, Koch AE, Haines GK, et al. Identification of genes modulated in rheumatoid arthritis using complementary DNA microarray analysis of lymphoblastoid B cell lines from disease-discordant monozygotic twins. Arthritis Rheum (2006) 54(7):2047-60. doi:10.1002/art.21953.
22. Kotecha N, Krutzik PO, Irish JM. Web-based analysis and publication of flow cytometry experiments. Curr Protoc Cytom (2010) Chapter 10:Unit1017. doi:10.1002/0471142956.cy1017s53.
23. Miller G, Robinson J, Heston L, Lipman M. Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference. Proc Natl Acad Sci U S A (1974) 71(10):4006-10. doi:10.1073/pnas.71.10.4006.
24. Blott EJ, Bossi G, Clark R, Zvelebil M, Griffiths GM. Fas ligand is targeted to secretory lysosomes via a proline-rich domain in its cytoplasmic tail. J Cell Sci (2001) 114(Pt 13):2405-16.
25. de Campos-Lima PO, Torsteinsdóttir S, Cuomo L, Klein G, Sulitzeanu D, Masucci MG. Antigen processing and presentation by EBV-carrying cell lines: cell-phenotype dependence and influence of the EBV-encoded LMP1. Int J Cancer (1993) 53(5):856-62. doi:10.1002/ijc.2910530525.
26. Rowe M, Khanna R, Jacob CA, Argaet V, Kelly A, Powis S, et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol (1995) 25(5):1374-84. doi:10.1002/eji.1830250536.
27. Tatsuta T, Cheng J, Mountz JD. Intracellular IL-1beta is an inhibitor of Fas-mediated apoptosis. J Immunol (1996) 157(9):3949-57.
28. + T cells inhibit growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated apoptosis. Int Immunol (1998) 10(8):1149-57. doi:10.1093/intimm/10.8.1149.
29. Kim YS, Park GB, Song HK, Hur I, Lee HK, Kang JS, et al. Cross-linking of CD54 on Burkitt lymphoma cell line Raji and Ramos induces FasL expression by reactive oxygen species and apoptosis of adjacent cells in Fas/FasL interaction. J Immunother (2007) 30(7):727-39. doi:10.1097/CJI.0b013e31814a69fa.
30. Kim YS, Park GB, Lee HK, Song H, Choi IH, Lee WJ, et al. Cross-linking of B7-H1 on EBV-transformed B cells induces apoptosis through reactive oxygen species production, JNK signaling activation, and FasL expression. J Immunol (2008) 181(9):6158-69.
31. Song H, Park G, Kim YS, Hur I, Kim H, Ryu JW, et al. B7-H4 reverse signaling induces the apoptosis of EBV-transformed B cells through Fas ligand up-regulation. Cancer Lett (2008) 266(2):227-37. doi:10.1016/j.canlet.2008.02.067.
32. Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol (2003) 3(10):801-12. doi:10.1038/nri1201.
33. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in memory B cells in vivo. Immunity (1998) 9(3):395-404. doi:10.1016/S1074-7613(00)80622-6.
34. Joseph AM, Babcock GJ, Thorley-Lawson DA. EBV persistence involves strict selection of latently infected B cells. J Immunol (2000) 165(6):2975-81.
35. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol (2001) 1(1):75-82. doi:10.1038/35095584.
36. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol (2007) 25:587-617. doi:10.1146/annurev.immunol.25.022106.141553.
37. Uchida J, Yasui T, Takaoka-Shichijo Y, Muraoka M, Kulwichit W, Raab-Traub N, et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science (1999) 286(5438):300-3. doi:10.1126/science.286.5438.300.
38. +) T cells and secrete interleukin-10. PLoS One (2013) 8(8):e70131. doi:10.1371/journal.pone.0070131.
39. Afford SC, Randhawa S, Eliopoulos AG, Hubscher SG, Young LS, Adams DH. CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface Fas ligand expression and amplifies Fas-mediated hepatocyte death during allograft rejection. J Exp Med (1999) 189(2):441-6. doi:10.1084/jem.189.2.441.
40. Eliopoulos AG, Davies C, Knox PG, Gallagher NJ, Afford SC, Adams DH, et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol (2000) 20(15):5503-15. doi:10.1128/MCB.20.15.5503-5515.2000.
41. Shibaki A, Katz SI. Activation through CD40 ligation induces functional Fas ligand expression by Langerhans cells. Eur J Immunol (2001) 31(10):3006-15. doi:10.1002/1521-4141(2001010)31:10<3006::AID-IMMU3006>3.0.CO;2-L.
42. Crawford DH, Macsween KF, Higgins CD, Thomas R, McAulay K, Williams H, et al. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis (2006) 43(3):276-82. doi:10.1086/505400.
43. Tanner JE, Alfieri C. Epstein-Barr virus induces Fas (CD95) in T cells and Fas ligand in B cells leading to T-cell apoptosis. Blood (1999) 94(10):3439-47.
44. Ohshima K, Suzumiya J, Sugihara M, Nagafuchi S, Ohga S, Kikuchi M. CD95 (Fas) ligand expression of Epstein-Barr virus (EBV)-infected lymphocytes: a possible mechanism of immune evasion in chronic active EBV infection. Pathol Int (1999) 49(1):9-13. doi:10.1046/j.1440-1827.1999.00816.x.
45. Johansson SM, Admyre C, Scheynius A, Gabrielsson S. Different types of in vitro generated human monocyte-derived dendritic cells release exosomes with distinct phenotypes. Immunology (2008) 123(4):491-9. doi:10.1111/j.1365-2567.2007.02714.x.
46. Bobrie A, Colombo M, Krumeich S, Raposo G, Théry C. Diverse subpopulations of vesicles secreted by different intracellular mechanisms are present in exosome preparations obtained by differential ultracentrifugation. J Extracell Vesicles (2012) 1:18397. doi:10.3402/jev.v1i0.18397.
47. Admyre C, Bohle B, Johansson SM, Focke-Tejkl M, Valenta R, Scheynius A, et al. B cell-derived exosomes can present allergen peptides and activate allergen-specific T cells to proliferate and produce TH2-like cytokines. J Allergy Clin Immunol (2007) 120(6):1418-24. doi:10.1016/j.jaci.2007.06.040.
48. Peng P, Yan Y, Keng S. Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-tumor immunity. Oncol Rep (2011) 25(3):749-62. doi:10.3892/or.2010.1119.
49. Tauro BJ, Greening DW, Mathias RA, Ji H, Mathivanan S, Scott AM, et al. Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes. Methods (2012) 56(2):293-304. doi:10.1016/j.ymeth.2012.01.002.
50. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med (1997) 186(12):2045-50. doi:10.1084/jem.186.12.2045.
51. de Souza N. Primer: genome editing with engineered nucleases. Nat Methods (2012) 9(1):27. doi:10.1038/nmeth.1848.
52. Joung JK, Sander JD. TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol (2013) 14(1):49-55. doi:10.1038/nrm3486.
53. +) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med (2000) 191(10):1649-60. doi:10.1084/jem.191.10.1649.
54. Théry C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol (2006) Chapter 3:Unit 322. doi:10.1002/0471143030.cb0322s30.
55. Delecluse HJ, Hammerschmidt W. The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy. Mol Pathol (2000) 53(5):270-9. doi:10.1136/mp.53.5.270.
56. Yu Z, Lu J, Yu H, Yan Q, Zuo L, Li G. A precise excision of the complete Epstein-Barr virus genome in a plasmid based on a bacterial artificial chromosome. J Virol Methods (2011) 176(1-2):103-7. doi:10.1016/j.jviromet.2011.06.015.
57. + cytotoxic T lymphocytes: a novel approach to vaccine design. J Virol (1998) 72(3):2246-52.